Recent Finacing
Recent Raise
Adimab operates a yeast-based platform for discovery, optimization and preclinical manufacturing of full-length human monoclonal antibodies, including workflows for bispecifics, ADCs and cell-surface targets.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Adimab.
